Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Targeting metals rescues the phenotype in an animal model of tauopathy.

Sedjahtera A, Gunawan L, Bray L, Hung LW, Parsons J, Okamura N, Villemagne VL, Yanai K, Liu XM, Chan J, Bush AI, Finkelstein DI, Barnham KJ, Cherny RA, Adlard PA.

Metallomics. 2018 Sep 19;10(9):1339-1347. doi: 10.1039/c8mt00153g.

PMID:
30168573
2.

The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.

Finkelstein DI, Billings JL, Adlard PA, Ayton S, Sedjahtera A, Masters CL, Wilkins S, Shackleford DM, Charman SA, Bal W, Zawisza IA, Kurowska E, Gundlach AL, Ma S, Bush AI, Hare DJ, Doble PA, Crawford S, Gautier EC, Parsons J, Huggins P, Barnham KJ, Cherny RA.

Acta Neuropathol Commun. 2017 Jun 28;5(1):53. doi: 10.1186/s40478-017-0456-2.

3.

Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage.

Diomede L, Romeo M, Rognoni P, Beeg M, Foray C, Ghibaudi E, Palladini G, Cherny RA, Verga L, Capello GL, Perfetti V, Fiordaliso F, Merlini G, Salmona M.

Antioxid Redox Signal. 2017 Sep 20;27(9):567-582. doi: 10.1089/ars.2016.6848. Epub 2017 Mar 3.

4.

Effects of Neonatal Iron Feeding and Chronic Clioquinol Administration on the Parkinsonian Human A53T Transgenic Mouse.

Billings JL, Hare DJ, Nurjono M, Volitakis I, Cherny RA, Bush AI, Adlard PA, Finkelstein DI.

ACS Chem Neurosci. 2016 Mar 16;7(3):360-6. doi: 10.1021/acschemneuro.5b00305. Epub 2016 Jan 7.

PMID:
26712118
5.

Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons.

Gunn AP, Wong BX, Johanssen T, Griffith JC, Masters CL, Bush AI, Barnham KJ, Duce JA, Cherny RA.

J Biol Chem. 2016 Mar 18;291(12):6134-45. doi: 10.1074/jbc.M115.655183. Epub 2015 Dec 23.

6.

Direct in vivo imaging of ferrous iron dyshomeostasis in ageing Caenorhabditis elegans.

James SA, Roberts BR, Hare DJ, de Jonge MD, Birchall IE, Jenkins NL, Cherny RA, Bush AI, McColl G.

Chem Sci. 2015 May 1;6(5):2952-2962. doi: 10.1039/c5sc00233h. Epub 2015 Mar 3.

7.

Parkinson's disease iron deposition caused by nitric oxide-induced loss of β-amyloid precursor protein.

Ayton S, Lei P, Hare DJ, Duce JA, George JL, Adlard PA, McLean C, Rogers JT, Cherny RA, Finkelstein DI, Bush AI.

J Neurosci. 2015 Feb 25;35(8):3591-7. doi: 10.1523/JNEUROSCI.3439-14.2015.

8.

Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation.

Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ, Grimm R, Doble PA, Cherny RA, Masters CL, Bush AI, Roberts BR.

ACS Chem Neurosci. 2015 Mar 18;6(3):398-402. doi: 10.1021/cn5003557. Epub 2015 Jan 23.

PMID:
25588002
9.

High order W02-reactive stable oligomers of amyloid-β are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid-β monomer.

Robb E, Perez K, Hung LW, Masters CL, Barnham KJ, Cherny RA, Bush AI, Adlard PA, Finkelstein DI.

J Alzheimers Dis. 2015;44(1):69-78. doi: 10.3233/JAD-132024.

PMID:
25182735
10.

Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.

Lu Z, Marks E, Chen J, Moline J, Barrows L, Raisbeck M, Volitakis I, Cherny RA, Chopra V, Bush AI, Hersch S, Fox JH.

Neurobiol Dis. 2014 Nov;71:34-42. doi: 10.1016/j.nbd.2014.06.022. Epub 2014 Jul 8.

PMID:
25014023
11.

Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease.

Ayton S, Lei P, Adlard PA, Volitakis I, Cherny RA, Bush AI, Finkelstein DI.

Mol Neurodegener. 2014 Jul 10;9:27. doi: 10.1186/1750-1326-9-27.

12.

Decreased serum zinc is an effect of ageing and not Alzheimer's disease.

Rembach A, Hare DJ, Doecke JD, Burnham SC, Volitakis I, Fowler CJ, Cherny RA, McLean C, Grimm R, Martins R, Ames D, Masters CL, Bush AI, Roberts BR.

Metallomics. 2014 Jul;6(7):1216-9. doi: 10.1039/c4mt00060a.

PMID:
24676028
13.

A novel approach to rapidly prevent age-related cognitive decline.

Adlard PA, Sedjahtera A, Gunawan L, Bray L, Hare D, Lear J, Doble P, Bush AI, Finkelstein DI, Cherny RA.

Aging Cell. 2014 Apr;13(2):351-9. doi: 10.1111/acel.12178. Epub 2013 Dec 4.

14.

Decreased copper in Alzheimer's disease brain is predominantly in the soluble extractable fraction.

Rembach A, Hare DJ, Lind M, Fowler CJ, Cherny RA, McLean C, Bush AI, Masters CL, Roberts BR.

Int J Alzheimers Dis. 2013;2013:623241. doi: 10.1155/2013/623241. Epub 2013 Oct 21.

15.

Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry.

Hare DJ, Grubman A, Ryan TM, Lothian A, Liddell JR, Grimm R, Matsuda T, Doble PA, Cherny RA, Bush AI, White AR, Masters CL, Roberts BR.

Metallomics. 2013 Dec;5(12):1656-62. doi: 10.1039/c3mt00227f. Epub 2013 Oct 17.

PMID:
24132241
16.

The effect of dopamine on MPTP-induced rotarod disability.

Ayton S, George JL, Adlard PA, Bush AI, Cherny RA, Finkelstein DI.

Neurosci Lett. 2013 May 24;543:105-9. doi: 10.1016/j.neulet.2013.02.066. Epub 2013 Apr 2.

PMID:
23562518
17.

Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease.

McColl G, Roberts BR, Pukala TL, Kenche VB, Roberts CM, Link CD, Ryan TM, Masters CL, Barnham KJ, Bush AI, Cherny RA.

Mol Neurodegener. 2012 Nov 21;7:57. doi: 10.1186/1750-1326-7-57.

18.

The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.

Hung LW, Villemagne VL, Cheng L, Sherratt NA, Ayton S, White AR, Crouch PJ, Lim S, Leong SL, Wilkins S, George J, Roberts BR, Pham CL, Liu X, Chiu FC, Shackleford DM, Powell AK, Masters CL, Bush AI, O'Keefe G, Culvenor JG, Cappai R, Cherny RA, Donnelly PS, Hill AF, Finkelstein DI, Barnham KJ.

J Exp Med. 2012 Apr 9;209(4):837-54. doi: 10.1084/jem.20112285. Epub 2012 Apr 2.

19.

Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.

Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BX, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI.

Nat Med. 2012 Jan 29;18(2):291-5. doi: 10.1038/nm.2613.

PMID:
22286308
20.

PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease.

Cherny RA, Ayton S, Finkelstein DI, Bush AI, McColl G, Massa SM.

J Huntingtons Dis. 2012;1(2):211-9. doi: 10.3233/JHD-120029.

PMID:
25063332
21.

Elevated labile Cu is associated with oxidative pathology in Alzheimer disease.

James SA, Volitakis I, Adlard PA, Duce JA, Masters CL, Cherny RA, Bush AI.

Free Radic Biol Med. 2012 Jan 15;52(2):298-302. doi: 10.1016/j.freeradbiomed.2011.10.446. Epub 2011 Oct 24.

PMID:
22080049
22.

The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity.

Crouch PJ, Savva MS, Hung LW, Donnelly PS, Mot AI, Parker SJ, Greenough MA, Volitakis I, Adlard PA, Cherny RA, Masters CL, Bush AI, Barnham KJ, White AR.

J Neurochem. 2011 Oct;119(1):220-30. doi: 10.1111/j.1471-4159.2011.07402.x. Epub 2011 Aug 25.

23.

Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein.

Fox JH, Connor T, Stiles M, Kama J, Lu Z, Dorsey K, Lieberman G, Sapp E, Cherny RA, Banks M, Volitakis I, DiFiglia M, Berezovska O, Bush AI, Hersch SM.

J Biol Chem. 2011 May 20;286(20):18320-30. doi: 10.1074/jbc.M110.199448. Epub 2011 Mar 30. Erratum in: J Biol Chem. 2011 Jul 29;286(30):27068. Liebermann, Gregory [corrected to Lieberman, Gregory].

24.

Regulation of insulin-regulated membrane aminopeptidase activity by its C-terminal domain.

Ascher DB, Cromer BA, Morton CJ, Volitakis I, Cherny RA, Albiston AL, Chai SY, Parker MW.

Biochemistry. 2011 Apr 5;50(13):2611-22. doi: 10.1021/bi101893w. Epub 2011 Mar 9.

PMID:
21348480
25.

Three-dimensional elemental bio-imaging of Fe, Zn, Cu, Mn and P in a 6-hydroxydopamine lesioned mouse brain.

Hare DJ, George JL, Grimm R, Wilkins S, Adlard PA, Cherny RA, Bush AI, Finkelstein DI, Doble P.

Metallomics. 2010 Nov;2(11):745-53. doi: 10.1039/c0mt00039f. Epub 2010 Oct 29.

PMID:
21072366
26.

Pyroglutamate-Aβ: role in the natural history of Alzheimer's disease.

Gunn AP, Masters CL, Cherny RA.

Int J Biochem Cell Biol. 2010 Dec;42(12):1915-8. doi: 10.1016/j.biocel.2010.08.015. Epub 2010 Sep 15. Review.

PMID:
20833262
27.

Copper in the brain and Alzheimer's disease.

Hung YH, Bush AI, Cherny RA.

J Biol Inorg Chem. 2010 Jan;15(1):61-76. doi: 10.1007/s00775-009-0600-y. Epub 2009 Oct 28. Review.

PMID:
19862561
28.

Plasma amyloid beta42 and amyloid beta40 levels are associated with early cognitive dysfunction after cardiac surgery.

Evered LA, Silbert BS, Scott DA, Maruff P, Laughton KM, Volitakis I, Cowie T, Cherny RA, Masters CL, Li QX.

Ann Thorac Surg. 2009 Nov;88(5):1426-32. doi: 10.1016/j.athoracsur.2009.07.003.

PMID:
19853085
29.

Targeting the progression of Parkinson's disease.

George JL, Mok S, Moses D, Wilkins S, Bush AI, Cherny RA, Finkelstein DI.

Curr Neuropharmacol. 2009 Mar;7(1):9-36. doi: 10.2174/157015909787602814.

30.

The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42.

McColl G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL, Barnham KJ, Cherny RA, Bush AI.

J Biol Chem. 2009 Aug 21;284(34):22697-702. doi: 10.1074/jbc.C109.028514. Epub 2009 Jul 2.

31.

Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions: implications for Alzheimer disease.

Hung YH, Robb EL, Volitakis I, Ho M, Evin G, Li QX, Culvenor JG, Masters CL, Cherny RA, Bush AI.

J Biol Chem. 2009 Aug 14;284(33):21899-907. doi: 10.1074/jbc.M109.019521. Epub 2009 Jun 19.

32.

Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation.

Crouch PJ, Tew DJ, Du T, Nguyen DN, Caragounis A, Filiz G, Blake RE, Trounce IA, Soon CP, Laughton K, Perez KA, Li QX, Cherny RA, Masters CL, Barnham KJ, White AR.

J Neurochem. 2009 Mar;108(5):1198-207. doi: 10.1111/j.1471-4159.2009.05870.x. Epub 2009 Jan 7.

33.

Intracellular amyloid formation in muscle cells of Abeta-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification.

Minniti AN, Rebolledo DL, Grez PM, Fadic R, Aldunate R, Volitakis I, Cherny RA, Opazo C, Masters C, Bush AI, Inestrosa NC.

Mol Neurodegener. 2009 Jan 6;4:2. doi: 10.1186/1750-1326-4-2.

34.

Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation.

Crouch PJ, Hung LW, Adlard PA, Cortes M, Lal V, Filiz G, Perez KA, Nurjono M, Caragounis A, Du T, Laughton K, Volitakis I, Bush AI, Li QX, Masters CL, Cappai R, Cherny RA, Donnelly PS, White AR, Barnham KJ.

Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):381-6. doi: 10.1073/pnas.0809057106. Epub 2009 Jan 2.

35.

Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.

Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI.

Neuron. 2008 Jul 10;59(1):43-55. doi: 10.1016/j.neuron.2008.06.018.

36.

Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease.

Barnham KJ, Kenche VB, Ciccotosto GD, Smith DP, Tew DJ, Liu X, Perez K, Cranston GA, Johanssen TJ, Volitakis I, Bush AI, Masters CL, White AR, Smith JP, Cherny RA, Cappai R.

Proc Natl Acad Sci U S A. 2008 May 13;105(19):6813-8. doi: 10.1073/pnas.0800712105. Epub 2008 May 7.

37.

Investigating copper-regulated protein expression in Menkes fibroblasts using antibody microarrays.

Du T, La Fontaine SL, Abdo M, Bellingham SA, Greenough M, Volitakis I, Cherny RA, Bush AI, Hudson PJ, Camakaris J, Mercer JF, Crouch PJ, Masters CL, Perreau VM, White AR.

Proteomics. 2008 May;8(9):1819-31. doi: 10.1002/pmic.200700895.

PMID:
18384105
38.

Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide.

Donnelly PS, Caragounis A, Du T, Laughton KM, Volitakis I, Cherny RA, Sharples RA, Hill AF, Li QX, Masters CL, Barnham KJ, White AR.

J Biol Chem. 2008 Feb 22;283(8):4568-77. Epub 2007 Dec 17.

39.

Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid.

Strozyk D, Launer LJ, Adlard PA, Cherny RA, Tsatsanis A, Volitakis I, Blennow K, Petrovitch H, White LR, Bush AI.

Neurobiol Aging. 2009 Jul;30(7):1069-77. Epub 2007 Dec 18.

40.

Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands.

Caragounis A, Du T, Filiz G, Laughton KM, Volitakis I, Sharples RA, Cherny RA, Masters CL, Drew SC, Hill AF, Li QX, Crouch PJ, Barnham KJ, White AR.

Biochem J. 2007 Nov 1;407(3):435-50.

41.

Mitochondrial oxidative stress causes hyperphosphorylation of tau.

Melov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinerfeld D, Schilling B, Mavros C, Masters CL, Volitakis I, Li QX, Laughton K, Hubbard A, Cherny RA, Gibson B, Bush AI.

PLoS One. 2007 Jun 20;2(6):e536.

42.

Mechanisms of copper ion mediated Huntington's disease progression.

Fox JH, Kama JA, Lieberman G, Chopra R, Dorsey K, Chopra V, Volitakis I, Cherny RA, Bush AI, Hersch S.

PLoS One. 2007 Mar 28;2(3):e334.

43.

Elevated cortical zinc in Alzheimer disease.

Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, Winblad B, Naslund J, Bush AI.

Neurology. 2006 Jul 11;67(1):69-75.

PMID:
16832080
44.

Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age.

Kaur D, Peng J, Chinta SJ, Rajagopalan S, Di Monte DA, Cherny RA, Andersen JK.

Neurobiol Aging. 2007 Jun;28(6):907-13. Epub 2006 Jun 12.

PMID:
16765489
45.

Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity.

White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL.

J Biol Chem. 2006 Jun 30;281(26):17670-80. Epub 2006 Apr 28.

46.

Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration.

Kaur D, Rajagopalan S, Chinta S, Kumar J, Di Monte D, Cherny RA, Andersen JK.

Brain Res. 2007 Apr 6;1140:188-94. Epub 2006 May 2.

PMID:
16631136
47.

Overexpression of Abeta is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model.

Li QX, Mok SS, Laughton KM, McLean CA, Volitakis I, Cherny RA, Cheung NS, White AR, Masters CL.

Aging Cell. 2006 Apr;5(2):153-65.

48.

Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology.

Maynard CJ, Cappai R, Volitakis I, Cherny RA, Masters CL, Li QX, Bush AI.

J Inorg Biochem. 2006 May;100(5-6):952-62. Epub 2006 Mar 6.

PMID:
16574231
49.

Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.

Opazo C, Luza S, Villemagne VL, Volitakis I, Rowe C, Barnham KJ, Strozyk D, Masters CL, Cherny RA, Bush AI.

Aging Cell. 2006 Feb;5(1):69-79.

50.

Dimerisation of N-acetyl-L-tyrosine ethyl ester and Abeta peptides via formation of dityrosine.

Ali FE, Leung A, Cherny RA, Mavros C, Barnham KJ, Separovic F, Barrow CJ.

Free Radic Res. 2006 Jan;40(1):1-9.

PMID:
16298754

Supplemental Content

Loading ...
Support Center